Osteoarthritis

P-10.3.2 - Lorecivivint (SM04690): An Intra-articular Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment - Phase 2b Patient-Reported Outcomes

Authors
Corresponding Author
Presentation Topic
Osteoarthritis
Poster Rating
 | 

Previous ePoster
P-10.3.1 - Wnt Pathway Modulation via CLK2 and DYRK1A Inhibition by Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis

Next ePosters
P-10.3.5 - Intra-articular knee injection of mesenchymal stem cells for degenerative osteoarthritis improved the knee function at 3-years follow up
P-10.3.6 - Bone Mineral Density is more closely associated with the development of knee osteoarthritis in women than men: National Health Examination
P-10.3.8 - Can osteoarthritis biomarkers monitor clinical improvement?
P-10.4.1 - Over-Confluence of expanded mesenchymal stem cells ameliorates their chondrogenic capacity in 3D cartilage tissue engineering
P-10.4.3 - Design and evaluation of electrospun structured polycaprolactone biomaterials for annulus fibrosus repair
P-10.4.4 - Magnetic levitational bioassembly of cartilage in Space
P-10.4.5 - Cartilage-on-chip: mimicking the complex mechanical stimulation present in articular cartilage
P-10.4.6 - The mechanism of spontaneous calcium signaling in chondrocytes and its regulation in cartilaginous matrix metabolism
P-10.4.8 - Identification of M9 high-mannose glycan regulating hypertrophy in articular cartilage
P-12.1.3 - Can a Biopolymer Scaffold Injected Arthroscopically Restore Articular Cartilage and Delay Hip Osteoarthritis?